Invion (ASX:IVX) closes H1 with key R&D milestones for cancer and infectious diseases

March 08, 2023 12:25 PM AEDT | By Ankit Sethi
Follow us on Google News:


  • Invion has released its H1FY23 report, highlighting progress with respect to its Photosoft™ technology and lead drug candidate INV043.
  • Photosoft™ has demonstrated positive results against antibiotic resistant MRSA bacteria, Candida albicans fungus and Escherichia coli bacteria, as well as SARS-CoV-2.
  • INV043 has shown effectiveness against six squamous cell carcinoma cell lines related to anal cancers.
  • In 2023, Invion plans to commence at least two clinical trials using INV043.

ASX-listed life sciences company Invion Limited (ASX: IVX) has released its half yearly report for the period ended 31 December 2022. The company, which is leading the global research & development (R&D) of PhotosoftTM technology to treat cancer and other diseases, achieved key R&D milestones during the reported period.

The primary highlights related to IVX’s progress with respect to the treatment of cancer and infectious diseases are listed below.

In vitro studies indicate INV043 effectiveness against anal cancer

A major progress during the first half was the results from the Peter MacCallum Cancer Centre’s in vitro studies. These demonstrated the company’s lead candidate INV043’s effectiveness against six squamous cell carcinoma cell lines, IVX mentions. These cell lines represent several anal cancers.

The outcomes from the Peter Mac studies show consistency with the drug’s positive results demonstrated by the Hudson Institute of Medical Research for other types of cancers. Those studies focused on triple negative breast cancer.


Image source: Company website

Invion Limited has commented that aside from the above two, other partners are also undertaking further work on INV043, with human clinical trials expected later in 2023.

The plan is to begin a minimum of two INV043 clinical trials in the ongoing calendar year -- one on skin cancer and the other probably related to anogenital cancer.

Photosoft™ shows activity against infectious diseases

During the first half of FY23, Invion also achieved multiple promising results from early studies using Photosoft™ on several infectious diseases. One significant progress was the findings -- in collaboration with the Australian Centre for Antimicrobial Resistance Ecology (a research division at the University of Adelaide) -- with respect to antibiotic resistant MRSA bacteria.

Invion has mentioned that the said bacteria is a superbug -- the World Health Organization considers antibiotic resistance as one the top threats to humanity -- and in vitro tests demonstrated Photosoft™ compounds’ activity against the said superbug’s multiple strains. Further, activity against Candida albicans fungus and Escherichia coli bacteria was also noted.

Separately, Photosoft™ has potential against SARS-CoV-2 (virus associated with Covid-19). Photosoft™ compounds have demonstrated antiviral activity against the virus’s Omicron BA.1 and Delta variants.

Photosoft™ territory expansion

Invion reported in February 2023 about entering into a conditional agreement with Hong Kong-based RMW Cho Group Limited. This relates to expansion of the existing Co-Development Agreement and Exclusive Licence and Distribution Agreement -- Atherosclerosis and Infectious Diseases that Invion has with RMW Cho Group. 

The new agreement would involve expansion of IVX’s co-development and distribution rights for Photosoft™ (with respect to infectious diseases) to territories including the US, Canada, and Hong Kong. Read more.

Invion ended the period with AU$8.03 million in cash. The company says that it remains funded to undertake the development work focused on cancers, atherosclerosis and infectious diseases not covered under agreements with its Hong Kong-based partner. 


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK